Keith Speights

Keith Speights


Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles

Why HEXO Stock Soared Today

Plans to launch cannabis-infused beverages lit a fire beneath the beaten-down marijuana stock.

Why Aphria Stock Sank Today

Investors' anxiety about forthcoming earnings results appeared to weigh on the Canadian marijuana stock.